This anti-angiogenic effect may also prove beneficial when combined with other anti-angiogenic approaches such as the use of bevacizumab, an anti-vascular endothelial growth factor (anti-VEGF) antibody drug, that has shown efficacy in disrupting tumor vascularization in breast cancer [69]. This evidence concerns the gene VEGFA and breast carcinoma.